JUNS Stock - Jupiter Neurosciences, Inc.
Unlock GoAI Insights for JUNS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $233,281 | $638,037 | $1.13M |
| Gross Profit | N/A | N/A | $233,281 | $638,037 | $1.13M |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | 100.0% |
| Operating Income | $-3,091,282 | $-3,870,771 | $-3,432,447 | $-3,907,097 | $-1,851,594 |
| Net Income | $-2,439,625 | $-4,783,689 | $-4,957,580 | $-4,379,427 | $-1,654,699 |
| Net Margin | N/A | N/A | -2125.2% | -686.4% | -146.9% |
| EPS | $-0.08 | $-0.14 | $-0.15 | $-0.44 | $-0.19 |
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Visit WebsiteEarnings History & Surprises
JUNSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-0.07 | — | — | — |
Q4 2025 | Dec 22, 2025 | $-0.08 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q3 2025 | Aug 18, 2025 | $-0.07 | $-0.07 | 0.0% | = MET |
Q2 2025 | May 15, 2025 | $-0.03 | $-0.05 | -66.7% | ✗ MISS |
Q1 2025 | Mar 28, 2025 | $-0.02 | $-0.05 | -150.0% | ✗ MISS |
Q4 2024 | Dec 23, 2024 | — | $-0.02 | — | — |
Q2 2024 | Jun 30, 2024 | — | $0.01 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-0.02 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.01 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.07 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.03 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.04 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.08 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.07 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.23 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.14 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.09 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.03 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.05 | — | — |
Latest News
Jupiter Neurosciences Files Prospectus Related To Resale Of Up To 10M Shares Of Our Common Stock By Selling Stockholder
📉 NegativeJupiter Neurosciences Announces FDA Clearance Of IND Application To Initiate Phase 2a Clinical Trial Of JOTROL For Parkinson's Disease
📈 PositiveJupiter Neurosciences Enters Financing Agreements With Potential To Access Up To $20M In Capital
📈 PositiveFrequently Asked Questions about JUNS
What is JUNS's current stock price?
What is the analyst price target for JUNS?
What sector is Jupiter Neurosciences, Inc. in?
What is JUNS's market cap?
Does JUNS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to JUNS for comparison